Spots Global Cancer Trial Database for Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Official Title: A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Study ID: NCT01774253
Conditions
Interventions
Study Description
Brief Summary: The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.
Detailed Description:
Keywords
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Phoenix Children's Hospital, Phoenix, Arizona, United States
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Contact Details
Name: Giselle Sholler, MD
Affiliation: Beat Childhood Cancer at Atrium Health
Role: STUDY_CHAIR
Name: Albert Cornelius, MD
Affiliation: Helen DeVos Children's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
